Latest news
Tarsus Strikes Up to $800M Deal for Alkeus, Entering Heated Stargardt Disease Race - finance.biggo.comfinance.biggo.com · Fri, 07 Aug 2026 18:41:00 GMTTarsus places $800m wager on Alkeus' Stargardt therapy - pharmaphorumpharmaphorum · Thu, 06 Aug 2026 15:06:32 GMTTarsus pays $450M for Alkeus and its ph. 3 retinal disease drug - Fierce BiotechFierce Biotech · Thu, 06 Aug 2026 14:30:00 GMTTarsus bets $450M on Alkeus’ Stargardt drug - Endpoints NewsEndpoints News · Thu, 06 Aug 2026 12:57:00 GMTTarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 11:01:00 GMTTarsus' Pending Deal Includes Phase 3 Oral Stargardt Drug Candidate - Stock TitanStock Titan · Thu, 06 Aug 2026 11:01:00 GMTBelite Bio presents updated phase 3 data on oral tinlarebant for Stargardt - Glance by Eyes On EyecareGlance by Eyes On Eyecare · Mon, 03 Aug 2026 11:24:06 GMTBelite Bio eyes FDA approval for oral Stargardt disease drug after positive Phase 3 trial - PluangPluang · Wed, 29 Jul 2026 07:00:00 GMT